Jun 28 |
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
|
Jun 21 |
Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked
|
Jun 12 |
Dianthus wins FDA nod to start mid-stage trial for lead asset
|
Jun 12 |
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
|
May 30 |
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 21 |
Companies Like Dianthus Therapeutics (NASDAQ:DNTH) Are In A Position To Invest In Growth
|
May 16 |
H.C. Wainwright starts Dianthus as buy, cites lead drug candidate
|
May 9 |
Dianthus Therapeutics GAAP EPS of -$0.54 misses by $0.10, revenue of $0.87M beats by $0.5M
|
May 9 |
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
|
May 8 |
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
|